Down-regulation of TSG101 by small interfering RNA inhibits the proliferation of breast cancer cells through the MAPK/ERK signal pathway

Histology and Histopathology

Volumn 26, Issue 1, 2011, Pages 87-94

  Zhang, Y ^a   Song, M ^a   Cui, Z S ^a   Li, C Y ^a   Xue, X X ^a   Yu, M ^a   Lu, Y ^a   Zhang, S Y ^a   Wang, E H ^a   Wen, Y Y ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; MAPK ERK; SiRNA; TSG101

Indexed keywords

DNA BINDING PROTEIN; ESCRT PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN;

APOPTOSIS; ARTICLE; BREAST TUMOR; CELL MOTION; CELL PROLIFERATION; DOWN REGULATION; DRUG ANTAGONISM; FEMALE; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA-BINDING PROTEINS; DOWN-REGULATION; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MAP KINASE SIGNALING SYSTEM; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 78651245212     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Aebersold D. M., Burri P., Beer K. T., Laissue J., Djonov V., Greiner R. H. and Semenza G. L. (2001). Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 61, 2911-2916.
2. Bennett N. A., Pattillo R. A., Lin R. S., Hsieh C. Y., Murphy T. and Lyn D. (2001). TSG101 expression in gynecological tumors: relationship to cyclin D1, cyclin E, p53 and p16 proteins. Cell. Mol. Biol. (Noisy-legrand) 47, 1187-1193.
3. Boucher M. J., Morisset J., Vachon P. H., Reed J. C., Laine J. and Rivard N. (2000). MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X (L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J. Cell. Biochem. 79, 355-369.
4. Feng G. H., Lih C. J. and Cohen S. N. (2000). TSG101 protein steadystate level is regulated posttranslationally by an evolutionarily conserved COOH-terminal sequence. Cancer Res. 60, 1736-1741.
5. Kang C. D., Yoo S. D., Hwang B. W., Kim K. W., Kim D. W., Kim C. M., Kim S. H. and Chung B. S. (2000). The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells. Leuk. Res. 24, 527-534.
6. Krempler A., Henry M. D., Triplett A. A. and Wagner K. U. (2002). Targeted deletion of the Tsg101 gene results in cell cycle arrest at G1/S and p53-independent cell death. J. Biol. Chem. 277, 43216-43223.
7. Li L. and Cohen S. N. (1996). Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 85, 319-329.
8. Lo Y. F., Chen T. C., Chen S. C. and Chao C. C. (2000). Aberrant expression of TSG101 in Taiwan Chinese breast cancer. Breast Cancer Res. Treat. 60, 259-266.
9. Ma X. R., Edmund Sim U. H., Pauline B., Patricia L. and Rahman J. (2008). Overexpression of WNT2 and TSG101 genes in colorectal carcinoma. Trop. Biomed. 25, 46-57.
10. Oh K. B., Stanton M. J., West W. W., Todd G. L. and Wagner K. U. (2007). Tsg101 is upregulated in a subset of invasive human breast cancers and its targeted overexpression in transgenic mice reveals weak oncogenic properties for mammary cancer initiation. Oncogene 26, 5950-5959.
11. Ostrakhovitch E. A. and Cherian M. G. (2004). Differential regulation of signal transduction pathways in wild type and mutated p53 breast cancer epithelial cells by copper and zinc. Arch. Biochem. Biophys. 423, 351-361.
12. Ruland J., Sirard C., Elia A., MacPherson D., Wakeham A., Li L., de la Pompa J. L., Cohen S. N. and Mak T. W. (2001). p53 accumulation, defective cell proliferation, and early embryonic lethality in mice lacking tsg101. Proc. Natl. Acad. Sci. USA 98, 1859-1864.
13. Shen H. Q., Wang Q., Han Z. Y., Xie H. H. and Fan D. M. (2004). Construction and identification of TSG101 siRNA eukaryotic expression vector. J. Shanxi Med. Univ. 24, 515-518.
14. Shen Y., Li N., Wu S., Zhou Y., Shan Y., Zhang Q., Ding C., Yuan Q., Zhao F., Zeng R. and Zhu X. (2008). Nudel binds Cdc42GAP to modulate Cdc42 activity at the leading edge of migrating cells. Dev. Cell 14, 342-353.
15. Wagner K. U., Krempler A., Qi Y., Park K., Henry M. D., Triplett A. A., Riedlinger G., Rucker I. E. and Hennighausen L. (2003). Tsg101 is essential for cell growth, proliferation, and cell survival of embryonic and adult tissues. Mol. Cell. Biol. 23, 150-162.
16. Young T. W., Mei F. C., Rosen D. G., Yang G., Li N., Liu J. and Cheng X. (2007). Up-regulation of tumor susceptibility gene 101 protein in ovarian carcinomas revealed by proteomics analyses. Mol. Cell. Proteomics 6, 294-304.
17. Young T. W., Rosen D. G., Mei F. C., Li N., Liu J., Wang X. F. and Cheng X. (2007). Up-regulation of tumor susceptibility gene 101 conveys poor prognosis through suppression of p21 expression in ovarian cancer. Clin. Cancer Res. 13, 3848-3854.
18. Zhu G., Reynolds L., Crnogorac-Jurcevic T., Gillett C. E., Dublin E. A., Marshall J. F., Barnes D., D'Arrigo C., Van Trappen P. O., Lemoine N. R. and Hart I. R. (2003). Combination of microdissection and microarray analysis to identify gene expression changes between differentially located tumour cells in breast cancer. Oncogene 22, 3742-3748.
19. Zhu G., Gilchrist R., Borley N., Chng H. W., Morgan M., Marshall J. F., Camplejohn R. S., Muir G. H. and Hart I. R. (2004). Reduction of TSG101 protein has a negative impact on tumor cell growth. Int. J. Cancer 109, 541-547.